Ig A is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. Most people with Ig A nephropathy receive care from a nephrologist, a doctor who specializes in treating people with kidney disease. Chloroquine and proguanil malaria tablets Plaquenil screening doctor Plaquenil calcium IgA nephropathy usually progresses slowly over years, but the course of the disease varies from person to person. Some people leak blood in their urine without developing problems, some eventually achieve complete remission and others develop end-stage kidney failure. Background and objectives Hydroxychloroquine is widely used in patients with rheumatoid arthritis. However, large-scale studies examining the long-term effects of hydroxychloroquine on the development of kidney disease in patients with rheumatoid arthritis are lacking. We aimed to assess the long-term association of hydroxychloroquine use with the risk of developing CKD in this population. What is IgA Nephropathy? Many diseases can affect your kidney function by attacking and damaging the glomeruli, the tiny filtering units inside your kidney where blood is cleaned. The conditions that affect your glomeruli are called glomerular diseases. Glomerular diseases include many conditions with many different causes. Immunoglobulin A Nephropathy, called IgAN for short, or Berger’s. The glomeruli are sets of looping blood vessels in nephrons—the tiny working units of the kidneys that filter wastes and remove extra fluid from the blood. Ig A nephropathy affects the kidneys by attacking the glomeruli. Plaquenil for iga nephropathy IgA Nephropathy Berger's Disease - DaVita, Hydroxychloroquine Use and Risk of CKD in Malarone for chloroquine resistance ncbiChloroquin malariaPlaquenil dosage based on weightHydroxychloroquine 200 mg ingredients ConfigCtrl2metaDescription}} UpToDate. IgA Nephropathy National Kidney Foundation. IgA Nephropathy - WebMD. Despite optimization of renin-angiotensin-aldosterone system RAAS inhibition, patients with immunoglobulin A nephropathy IgAN and persistent proteinuria remain at risk for kidney failure. We evaluated the efficacy and safety of hydroxychloroquine HCQ, an immunomodulator, when added to the treatment regimen of patients with IgAN. IgA Nephropathy. IgA nephropathy is the most common form of primary glomerulonephritis globally and is responsible for 10% of all dialysis patients worldwide. Forty percent of IgA nephropathy pateints develop end-stage renal disease and require dialysis within 20 years of diagnosis. There currently is no approved treatment for IgA nephropathy. Dendritic cells, Toll-like receptor TLR, interleukin-6 IFN-α, interferon-alpha IFN-α and tumor necrosis factor-alpha TNF-α play an important role in the pathogenesis of IgA nephropathy IgAN. Hydroxychloroquine HCQ is an antimalarial agent and had a notable impact on immune activation by the reduction of circulating activated immune cells that including decreased TLR-expressing.